Clinical outcome of HIV-infected anti retroviral-naive patients with discordant immunologic and virologic responses to highly active antiretroviral therapy

被引:98
作者
Tan, Ruimin [1 ]
Westfall, Andrew O. [2 ]
Willig, James H. [3 ]
Mugavero, Michael J. [3 ]
Saag, Michael S. [3 ]
Kaslow, Richard A. [1 ]
Kempf, Miriam C. [1 ]
机构
[1] Univ Alabama Birmingham, Sch Publ Hlth, Dept Epidemiol, Birmingham, AL 35294 USA
[2] Univ Alabama Birmingham, Sch Publ Hlth, Dept Biostat, Birmingham, AL 35294 USA
[3] Univ Alabama Birmingham, Sch Med, Dept Med, Birmingham, AL USA
关键词
clinical outcomes; discordant responses; highly active antiretroviral therapy; HIV;
D O I
10.1097/QAI.0b013e31816856c5
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background: The prognostic significance of a response to highly active antiretroviral therapy (HAART) that is immunologically and virologically discordant is not well understood. Methods: Four hundred four antiretroviral-naive patients initiating HAART at an urban HIV outpatient clinic in 1995 to 2004 were analyzed. The association of treatment responses at 3 to 9 months after HAART initiation with time to development of an opportunistic infection (01) or death was determined using Cox proportional hazards modeling. Logistic regression modeling was used to examine the association between discordant responses and patient characteristics. Results: Of 404 patients, 70.5% experienced favorable concordant responses (CD4 cell count [CD4](+)/viral load [VL](+): increase in CD4 count of >= 50 cells/mu L and achievement of undetectable plasma HIV RNA level), 15.8% an immunologic response only (CD4(+)VL(-)), 8.7% a virologic response only (CD4(-)/VL+), and 5.0% a concordant unfavorable response (CD4(-)/VL-). Both types of discordant responses (CD4/VL- and CD4(-)/VL+), nonresponse (CD4(-)/VL-), and baseline CD4 cell count were significantly associated with earlier development of an 01 or death (relative hazard [RH] = 2.81, 95% confidence interval [CI]: 1.31 to 3.97; RH - 4.83, 95% Cl: 2.10 to 11.12; and RH - 0.93, 95% CI: 0.88 to 0.99, respectively). CD4(+)/VL- and CD4-/VL- were associated with nonwhite race in multivariate logistic regression models (adjusted OR = 2.83, 95% Cl: 1.46 to 5.47 and adjusted OR = 6.50, 95% Cl: 1.65 to 25.69, respectively). Conclusion: Discordant immunologic and virologic responses at 3 to 9 months after HAART initiation play important roles in predicting long-term clinical outcomes in treatment-naive patients.
引用
收藏
页码:553 / 558
页数:6
相关论文
共 20 条
[1]   Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy:: a collaborative analysis of prospective studies [J].
Egger, M ;
May, M ;
Chêne, G ;
Phillips, AN ;
Ledergerber, B ;
Dabis, F ;
Costagliola, D ;
Monforte, AD ;
de Wolf, F ;
Reiss, P ;
Lundgren, JD ;
Justice, AC ;
Staszewski, S ;
Leport, C ;
Hogg, RS ;
Sabin, CA ;
Gill, MJ ;
Salzberger, B ;
Sterne, JAC .
LANCET, 2002, 360 (9327) :119-129
[2]   Clinical outcome of patients with HIV-1 infection according to immunologic and virologic response after 6 months of highly active antiretroviral therapy [J].
Grabar, S ;
Le Moing, V ;
Goujard, C ;
Leport, C ;
Kazatchkine, MD ;
Costagliola, D ;
Weiss, L .
ANNALS OF INTERNAL MEDICINE, 2000, 133 (06) :401-410
[3]   Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection [J].
Gulick, RM ;
Ribaudo, HJ ;
Shikuma, CM ;
Lustgarten, S ;
Squires, KE ;
Meyer, WA ;
Acosta, EP ;
Schackman, BR ;
Pilcher, CD ;
Murphy, RL ;
Maher, WE ;
Witt, MD ;
Reichman, RC ;
Snyder, S ;
Klingman, KL ;
Kuritzkes, DR .
NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (18) :1850-1861
[4]   Three- vs four-drug antiretroviral regimens for the initial treatment of HIV-1 infection - A randomized controlled trial [J].
Gulick, Roy M. ;
Ribaudo, Heather J. ;
Shikuma, Cecilia M. ;
Lalama, Christina ;
Schackman, Bruce R. ;
Meyer, William A., III ;
Acosta, Edward P. ;
Schouten, Jeffrey ;
Squires, Kathleen E. ;
Pilcher, Christopher D. ;
Murphy, Robert L. ;
Koletar, Susan L. ;
Carlson, Margrit ;
Reichman, Richard C. ;
Bastow, Barbara ;
Klingman, Karin L. ;
Kuritzkes, Daniel R. .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2006, 296 (07) :769-781
[5]   Treatment for adult HIV infection - 2006 recommendations of the International AIDS Society-USA panel [J].
Hammer, Scott M. ;
Saag, Michael S. ;
Schechter, Mauro ;
Montaner, Julio S. G. ;
Schooley, Robert T. ;
Jacobsen, Donna M. ;
Thompson, Melanie A. ;
Carpenter, Charles C. J. ;
Fischl, Margaret A. ;
Gazzard, Brian G. ;
Gatell, Jose M. ;
Hirsch, Martin S. ;
Katzenstein, David A. ;
Richman, Douglas D. ;
Vella, Stefano ;
Yeni, Patrick G. ;
Volberding, Paul A. .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2006, 296 (07) :827-843
[6]   CD4 cell count as a surrogate endpoint in HIV clinical trials: a meta-analysis of studies of the AIDS Clinical Trials Group [J].
Hughes, MD ;
Daniels, MJ ;
Fischl, MA ;
Kim, S ;
Schooley, RT .
AIDS, 1998, 12 (14) :1823-1832
[7]  
Marimoutou C, 2001, J ACQ IMMUN DEF SYND, V27, P161, DOI 10.1097/00126334-200106010-00011
[8]   Early immunologic and virologic responses to highly active antiretroviral therapy and subsequent disease progression among HIV-infected injection drug users [J].
Mehta, S. H. ;
Lucas, G. ;
Astemborski, J. ;
Kirk, G. D. ;
Vlahov, D. ;
Galai, N. .
AIDS CARE-PSYCHOLOGICAL AND SOCIO-MEDICAL ASPECTS OF AIDS/HIV, 2007, 19 (05) :637-645
[9]   Plasma viral load and CD4(+) lymphocytes as prognostic markers of HIV-1 infection [J].
Mellors, JW ;
Munoz, A ;
Giorgi, JV ;
Margolick, JB ;
Tassoni, CJ ;
Gupta, P ;
Kingsley, LA ;
Todd, JA ;
Saah, AJ ;
Detels, R ;
Phair, JP ;
Rinaldo, CR .
ANNALS OF INTERNAL MEDICINE, 1997, 126 (12) :946-954
[10]   Discordant immunologic and virologic responses to highly active antiretroviral therapy are associated with increased mortality and poor adherence to therapy [J].
Moore, DM ;
Hogg, RS ;
Yip, B ;
Wood, E ;
Tyndall, M ;
Braitstein, P ;
Montaner, JSG .
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2005, 40 (03) :288-293